GB9828074D0 - Therapeutically useful compounds - Google Patents

Therapeutically useful compounds

Info

Publication number
GB9828074D0
GB9828074D0 GBGB9828074.6A GB9828074A GB9828074D0 GB 9828074 D0 GB9828074 D0 GB 9828074D0 GB 9828074 A GB9828074 A GB 9828074A GB 9828074 D0 GB9828074 D0 GB 9828074D0
Authority
GB
United Kingdom
Prior art keywords
therapeutically useful
useful compounds
compounds
therapeutically
useful
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB9828074.6A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to GBGB9828074.6A priority Critical patent/GB9828074D0/en
Publication of GB9828074D0 publication Critical patent/GB9828074D0/en
Priority to CO99078241A priority patent/CO5170533A1/es
Priority to ARP990106429A priority patent/AR023727A1/es
Priority to BR9916282-2A priority patent/BR9916282A/pt
Priority to CA002355630A priority patent/CA2355630A1/en
Priority to AU30391/00A priority patent/AU760169B2/en
Priority to PL99348059A priority patent/PL348059A1/xx
Priority to ES99964583T priority patent/ES2226488T3/es
Priority to IL14290899A priority patent/IL142908A0/xx
Priority to HK02100145.2A priority patent/HK1038744A1/zh
Priority to CN99814654A priority patent/CN1330637A/zh
Priority to KR1020017007579A priority patent/KR20010101258A/ko
Priority to CZ20012209A priority patent/CZ20012209A3/cs
Priority to DE69919580T priority patent/DE69919580T2/de
Priority to HU0104867A priority patent/HUP0104867A3/hu
Priority to PE1999001274A priority patent/PE20001387A1/es
Priority to EP99964583A priority patent/EP1140837B1/en
Priority to JP2000589516A priority patent/JP4431282B2/ja
Priority to PCT/EP1999/010000 priority patent/WO2000037444A1/en
Priority to US09/868,395 priority patent/US6867192B1/en
Priority to AT99964583T priority patent/ATE273954T1/de
Priority to NZ511478A priority patent/NZ511478A/en
Priority to TR2001/01709T priority patent/TR200101709T2/xx
Priority to GT199900217A priority patent/GT199900217A/es
Priority to ZA200103948A priority patent/ZA200103948B/en
Priority to NO20012995A priority patent/NO20012995L/no
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205—Radicals derived from carbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GBGB9828074.6A 1998-12-18 1998-12-18 Therapeutically useful compounds Ceased GB9828074D0 (en)

Priority Applications (26)

Application Number Priority Date Filing Date Title
GBGB9828074.6A GB9828074D0 (en) 1998-12-18 1998-12-18 Therapeutically useful compounds
CO99078241A CO5170533A1 (es) 1998-12-18 1999-12-15 Derivados del acido fenil propanoico empleados en el tratami ento de padecimientos inflamatorios
ARP990106429A AR023727A1 (es) 1998-12-18 1999-12-15 Compuestos empleados en el tratamiento de padecimientos inflamatorios
TR2001/01709T TR200101709T2 (tr) 1998-12-18 1999-12-16 İltihabik hastalıkların tedavisinde yararlı olan bileşikler
CZ20012209A CZ20012209A3 (cs) 1998-12-18 1999-12-16 Sloučeniny s protizánětlivým účinkem
HU0104867A HUP0104867A3 (en) 1998-12-18 1999-12-16 Heterocyclic compounds useful in the treatment of inflammatory diseases, process for their preparation, pharmaceutical compositions comprising thereof and their use
AU30391/00A AU760169B2 (en) 1998-12-18 1999-12-16 Compounds useful in the treatment of inflammatory diseases
PL99348059A PL348059A1 (en) 1998-12-18 1999-12-16 Compounds useful in the treatment of inflammatory diseases
ES99964583T ES2226488T3 (es) 1998-12-18 1999-12-16 Compuestos utiles en el tratamiento de enfermedades inflamatorias.
IL14290899A IL142908A0 (en) 1998-12-18 1999-12-16 Compounds useful in the treatment of inflammatory diseases
HK02100145.2A HK1038744A1 (zh) 1998-12-18 1999-12-16 用於治療炎性疾病的化合物
CN99814654A CN1330637A (zh) 1998-12-18 1999-12-16 用于治疗炎性疾病的化合物
KR1020017007579A KR20010101258A (ko) 1998-12-18 1999-12-16 염증 질환 치료용 화합물
BR9916282-2A BR9916282A (pt) 1998-12-18 1999-12-16 Composto, uso de um um composto e método de tratamento
DE69919580T DE69919580T2 (de) 1998-12-18 1999-12-16 Verbindungen zur anwendung bei der behandlung entzündlicher erkrankungen
CA002355630A CA2355630A1 (en) 1998-12-18 1999-12-16 Compounds useful in the treatment of inflammatory diseases
PE1999001274A PE20001387A1 (es) 1998-12-18 1999-12-16 Compuestos empleados en el tratamiento de padecimientos inflamatorios
EP99964583A EP1140837B1 (en) 1998-12-18 1999-12-16 Compounds useful in the treatment of inflammatory diseases
JP2000589516A JP4431282B2 (ja) 1998-12-18 1999-12-16 炎症性疾患の治療に有用な化合物
PCT/EP1999/010000 WO2000037444A1 (en) 1998-12-18 1999-12-16 Compounds useful in the treatment of inflammatory diseases
US09/868,395 US6867192B1 (en) 1998-12-18 1999-12-16 Compounds useful in the treatment of inflammatory diseases
AT99964583T ATE273954T1 (de) 1998-12-18 1999-12-16 Verbindungen zur anwendung bei der behandlung entzündlicher erkrankungen
NZ511478A NZ511478A (en) 1998-12-18 1999-12-16 Compounds useful in the treatment of inflammatory diseases
GT199900217A GT199900217A (es) 1998-12-18 1999-12-17 Compuestos empleados en el tratamiento de padecimientos inflamatorios.
ZA200103948A ZA200103948B (en) 1998-12-18 2001-05-15 Compounds useful in the treatment of inflammatory diseases.
NO20012995A NO20012995L (no) 1998-12-18 2001-06-15 Forbindelser nyttige for behandling av inflammatoriske sykdommer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9828074.6A GB9828074D0 (en) 1998-12-18 1998-12-18 Therapeutically useful compounds

Publications (1)

Publication Number Publication Date
GB9828074D0 true GB9828074D0 (en) 1999-02-17

Family

ID=10844608

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9828074.6A Ceased GB9828074D0 (en) 1998-12-18 1998-12-18 Therapeutically useful compounds

Country Status (26)

Country Link
US (1) US6867192B1 (https=)
EP (1) EP1140837B1 (https=)
JP (1) JP4431282B2 (https=)
KR (1) KR20010101258A (https=)
CN (1) CN1330637A (https=)
AR (1) AR023727A1 (https=)
AT (1) ATE273954T1 (https=)
AU (1) AU760169B2 (https=)
BR (1) BR9916282A (https=)
CA (1) CA2355630A1 (https=)
CO (1) CO5170533A1 (https=)
CZ (1) CZ20012209A3 (https=)
DE (1) DE69919580T2 (https=)
ES (1) ES2226488T3 (https=)
GB (1) GB9828074D0 (https=)
GT (1) GT199900217A (https=)
HK (1) HK1038744A1 (https=)
HU (1) HUP0104867A3 (https=)
IL (1) IL142908A0 (https=)
NO (1) NO20012995L (https=)
NZ (1) NZ511478A (https=)
PE (1) PE20001387A1 (https=)
PL (1) PL348059A1 (https=)
TR (1) TR200101709T2 (https=)
WO (1) WO2000037444A1 (https=)
ZA (1) ZA200103948B (https=)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1244656A1 (en) 1999-12-28 2002-10-02 Pfizer Products Inc. Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases
GB0014869D0 (en) * 2000-06-16 2000-08-09 Glaxo Group Ltd Novel pharmaceutical formulation
GB0014849D0 (en) * 2000-06-16 2000-08-09 Glaxo Group Ltd Pharmaceutical aerosol formulation
GB0014883D0 (en) * 2000-06-16 2000-08-09 Glaxo Group Ltd Novel pharmaceutical formulation
GB0014881D0 (en) * 2000-06-16 2000-08-09 Glaxo Group Ltd Pharmaceutical aerosol formulation
GB0014851D0 (en) * 2000-06-16 2000-08-09 Glaxo Group Ltd Novel pharmaceutical formulation
GB0014947D0 (en) * 2000-06-16 2000-08-09 Glaxo Group Ltd Novel pharmaceutical formulation
GB0014892D0 (en) * 2000-06-16 2000-08-09 Glaxo Group Ltd Novel pharmaceutical formulation
GB0127423D0 (en) * 2001-11-15 2002-01-09 Glaxo Group Ltd Process
GB0218630D0 (en) 2002-08-10 2002-09-18 Tanabe Seiyaku Co Novel compounds
AU2004240940A1 (en) 2003-05-20 2004-12-02 Genentech, Inc. Thiocarbamate inhibitors of alpha-4 integrins
TW201422238A (zh) 2004-06-04 2014-06-16 Genentech Inc Ｃｄ２０抗體於治療多發性硬化症之用途及用於該用途之物品
US9158106B2 (en) 2005-02-23 2015-10-13 Pixtronix, Inc. Display methods and apparatus
US8482496B2 (en) 2006-01-06 2013-07-09 Pixtronix, Inc. Circuits for controlling MEMS display apparatus on a transparent substrate
US9261694B2 (en) 2005-02-23 2016-02-16 Pixtronix, Inc. Display apparatus and methods for manufacture thereof
US20070205969A1 (en) 2005-02-23 2007-09-06 Pixtronix, Incorporated Direct-view MEMS display devices and methods for generating images thereon
US8310442B2 (en) 2005-02-23 2012-11-13 Pixtronix, Inc. Circuits for controlling display apparatus
US7742016B2 (en) 2005-02-23 2010-06-22 Pixtronix, Incorporated Display methods and apparatus
US8159428B2 (en) 2005-02-23 2012-04-17 Pixtronix, Inc. Display methods and apparatus
US9082353B2 (en) 2010-01-05 2015-07-14 Pixtronix, Inc. Circuits for controlling display apparatus
US8519945B2 (en) 2006-01-06 2013-08-27 Pixtronix, Inc. Circuits for controlling display apparatus
US9229222B2 (en) 2005-02-23 2016-01-05 Pixtronix, Inc. Alignment methods in fluid-filled MEMS displays
US7999994B2 (en) 2005-02-23 2011-08-16 Pixtronix, Inc. Display apparatus and methods for manufacture thereof
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
US8526096B2 (en) 2006-02-23 2013-09-03 Pixtronix, Inc. Mechanical light modulators with stressed beams
US9176318B2 (en) * 2007-05-18 2015-11-03 Pixtronix, Inc. Methods for manufacturing fluid-filled MEMS displays
TW201014605A (en) 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
US8169679B2 (en) 2008-10-27 2012-05-01 Pixtronix, Inc. MEMS anchors
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
WO2011097252A2 (en) 2010-02-02 2011-08-11 Pixtronix, Inc. Methods for manufacturing cold seal fluid-filled display apparatus
KR20120139854A (ko) 2010-02-02 2012-12-27 픽스트로닉스 인코포레이티드 디스플레이 장치를 제어하기 위한 회로
WO2013101771A2 (en) 2011-12-30 2013-07-04 Genentech, Inc. Compositions and method for treating autoimmune diseases
KR20140119777A (ko) 2012-01-31 2014-10-10 제넨테크, 인크. 항-ig-e m1'' 항체 및 그의 사용 방법
US9134552B2 (en) 2013-03-13 2015-09-15 Pixtronix, Inc. Display apparatus with narrow gap electrostatic actuators
US10100012B2 (en) * 2014-05-30 2018-10-16 Sphaera Pharma Pvt. Ltd. Compounds as anti-tubercular agents
ES2835274T3 (es) * 2015-07-08 2021-06-22 Axerovision Inc Composiciones farmacéuticas que contienen un antagonista de la integrina alfa 4 para el tratamiento de afecciones inflamatorias oculares
EP4732904A2 (en) 2015-10-06 2026-04-29 F. Hoffmann-La Roche AG Method for treating multiple sclerosis
EP4067368A1 (en) 2016-06-01 2022-10-05 Athira Pharma, Inc. Compounds
CN109722455B (zh) * 2017-10-31 2022-03-11 中国科学院天津工业生物技术研究所 微生物发酵生产谷内酯的方法、工程菌及应用
US20230033021A1 (en) 2018-06-20 2023-02-02 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
AU2019373242B2 (en) 2018-10-30 2023-07-13 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
CN112969700B (zh) 2018-10-30 2024-08-20 吉利德科学公司 作为α4β7整合素抑制剂的咪唑并吡啶衍生物
KR102659859B1 (ko) 2018-10-30 2024-04-25 길리애드 사이언시즈, 인코포레이티드 알파4β7 인테그린의 억제를 위한 화합물
EP4541422A3 (en) 2018-10-30 2025-06-25 Gilead Sciences, Inc. Quinoline derivatives as alpha4beta7 integrin inhibitors
KR102908219B1 (ko) 2019-08-14 2026-01-08 길리애드 사이언시즈, 인코포레이티드 알파 4 베타 7 인테그린의 저해용 화합물
KR20230110514A (ko) * 2020-10-21 2023-07-24 아주라 오프탈믹스 엘티디 안구 장애의 치료를 위한 화합물 및 방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1593858A1 (de) * 1967-03-02 1970-10-29 Hoechst Ag Verfahren zur Herstellung tyrosinhaltiger Peptide und deren Derivaten
US4105602A (en) 1975-02-10 1978-08-08 Armour Pharmaceutical Company Synthesis of peptides with parathyroid hormone activity
US6248713B1 (en) * 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
EP1017382B1 (en) 1997-05-29 2006-03-01 Merck & Co., Inc. (a New Jersey corp.) Biarylalkanoic acids as cell adhesion inhibitors
EP1001764A4 (en) 1997-05-29 2005-08-24 Merck & Co Inc HETEROCYCLIC AMIDE COMPOUNDS AS INHIBITORS OF CELL ADHESION
CA2291708A1 (en) 1997-05-29 1998-12-03 Merck & Co., Inc. Sulfonamides as cell adhesion inhibitors
JP2002501518A (ja) 1997-05-30 2002-01-15 セルテック セラピューティックス リミテッド 抗炎症性チロシン誘導体

Also Published As

Publication number Publication date
AU760169B2 (en) 2003-05-08
DE69919580D1 (de) 2004-09-23
BR9916282A (pt) 2001-10-02
GT199900217A (es) 2001-06-09
PE20001387A1 (es) 2000-12-22
AU3039100A (en) 2000-07-12
EP1140837B1 (en) 2004-08-18
HUP0104867A3 (en) 2002-06-28
CO5170533A1 (es) 2002-06-27
AR023727A1 (es) 2002-09-04
EP1140837A1 (en) 2001-10-10
US6867192B1 (en) 2005-03-15
HUP0104867A2 (hu) 2002-04-29
NZ511478A (en) 2003-08-29
CA2355630A1 (en) 2000-06-29
WO2000037444A1 (en) 2000-06-29
DE69919580T2 (de) 2005-09-01
JP2002533326A (ja) 2002-10-08
ES2226488T3 (es) 2005-03-16
CZ20012209A3 (cs) 2001-09-12
ZA200103948B (en) 2002-11-15
TR200101709T2 (tr) 2001-12-21
PL348059A1 (en) 2002-05-06
KR20010101258A (ko) 2001-11-14
CN1330637A (zh) 2002-01-09
NO20012995D0 (no) 2001-06-15
HK1038744A1 (zh) 2002-03-28
NO20012995L (no) 2001-08-15
JP4431282B2 (ja) 2010-03-10
ATE273954T1 (de) 2004-09-15
IL142908A0 (en) 2002-04-21

Similar Documents

Publication Publication Date Title
GB9828074D0 (en) Therapeutically useful compounds
GB9804734D0 (en) Compounds
GB9804175D0 (en) Compounds
GB9818689D0 (en) Compounds
GB9818881D0 (en) Compounds
GB9821977D0 (en) Compounds
GB9809823D0 (en) Compounds
GB9810876D0 (en) Compounds
GB9801712D0 (en) Compounds
GB9809217D0 (en) Compounds
GB9822140D0 (en) Compounds
GB9812522D0 (en) Compounds
GB9915542D0 (en) Therapeutically useful compounds
GB9700862D0 (en) Pharmaceutically useful compounds
GB9701053D0 (en) Pharmaceutically useful compounds
GB9814649D0 (en) Compounds
GB9807756D0 (en) Compounds
GB9818733D0 (en) Compounds
GB9818088D0 (en) Compounds
GB9816990D0 (en) Compounds
GB9816983D0 (en) Compounds
GB9815712D0 (en) Compounds
GB9815467D0 (en) Compounds
GB9821698D0 (en) Compounds
GB9821702D0 (en) Compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)